0001567619-17-000225.txt : 20170221 0001567619-17-000225.hdr.sgml : 20170221 20170221081659 ACCESSION NUMBER: 0001567619-17-000225 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170221 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170221 DATE AS OF CHANGE: 20170221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 17623549 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 s001550x2_8k.htm 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 21, 2017
 
 
Bristol-Myers Squibb Company
(Exact Name of Registrant as Specified in Its Charter)

Delaware
1-1136
22-0790350
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission File Number)
(I.R.S.  Employer
Identification Number)

345 Park Avenue
New York, NY 10154
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 5.02.          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 21, 2017, the board of directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) temporarily increased the size of the Board from eleven directors to fourteen directors until the 2017 annual meeting of stockholders and appointed Messrs. Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels as members of the Board to fill the newly created directorships, effective immediately. Each of Messrs. Bertolini, Emmens and Samuels will serve as directors until the 2017 annual meeting of stockholders and until his successor is duly elected and qualified. At the 2017 annual meeting of stockholders, eleven directors will stand for election, including Messrs. Bertolini, Emmens and Samuels, and the size of the Board will return to eleven directors.
 
The Board has affirmatively determined that each of Messrs. Bertolini, Emmens and Samuels qualify as independent directors under the director independence standards set forth in the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the applicable listing standards of the New York Stock Exchange.
 
As of the date hereof, the Board has not determined any committee appointments for Messrs. Bertolini, Emmens or Samuels.
 
None of Messrs. Bertolini, Emmens or Samuels was selected as a director pursuant to any arrangement or understanding between him and any other person. There are no related party transactions between the Company and any of Messrs. Bertolini, Emmens or Samuels.
 
Each of Messrs. Bertolini, Emmens and Samuels will receive compensation for his services on the Board in accordance with the Company’s standard compensatory arrangement for non-employee directors, including an annual retainer of $100,000 and an annual award of deferred share units valued at $170,000 on the date of grant. Upon joining the Board, each of Messrs. Bertolini, Emmens and Samuels will receive a pro rata portion of the 2016 annual deferred share unit award.
 
Item 8.01.          Other Items.
 
On February 21, 2017, the Company announced that it has entered into accelerated share repurchase agreements with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2.0 billion of the Company’s shares of common stock. Approximately 80% of the shares to be repurchased under the transaction will be received by the Company on February 28, 2017. The final settlement of the transactions under the agreements is expected to be completed prior to the end of the second quarter of 2017, at which time the total number of the Company’s shares repurchased under the agreements will be determined based on a discount to the volume-weighted average price of the Company’s common stock during the term of the repurchase transactions.
 
The accelerated share repurchase agreements were entered into pursuant to the Company’s existing share repurchase authorization, as previously announced on October 27, 2016.
 
On February 21, 2017, the Company issued a press release to announce the appointment of Messrs. Bertolini, Emmens and Samuels to the Board and the entry into the accelerated share repurchase agreements. A copy of the press release is attached as Exhibit 99.1.
 
Statement on Cautionary Factors
 
This Report contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the Company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.
 
These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions, the ultimate outcome of any litigation matter and our level of indebtedness. These factors also include the Company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the Company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01.          Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit
 No.
  
Description
99.1
 
  
Press release dated February 21, 2017
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Bristol-Myers Squibb Company
     
 
By:
/s/ Katherine R. Kelly
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary
 
Dated: February 21, 2017

EXHIBIT INDEX
 
Exhibit
 No.
  
Description
99.1
  
Press release dated February 21, 2017

EX-99.1 2 s001550x2_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

 
Bristol-Myers Squibb Appoints Three New Independent Directors

Announces $2 Billion  Accelerated Share Repurchase Program

(NEW YORK, February 21, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its Board of Directors, effective immediately. In connection with these appointments, the Board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. Bristol-Myers Squibb also announced that it has entered into an accelerated share repurchase (“ASR”) program to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock.
 
Giovanni Caforio, M.D., chief executive officer of Bristol-Myers Squibb, said, “Bristol-Myers Squibb continues to take decisive action to best position the company for growth driven by our leading portfolio of Immuno-Oncology medicines, including Opdivo, and by an exciting diversified portfolio of medicines such as Eliquis and Orencia. We are committed to advancing the promising opportunities represented by our portfolio and pipeline in oncology as well as continuing our efforts to diversify through promising pipeline agents in heart failure, immunoscience and fibrosis. Our new directors add important experience and skills managing large businesses and operations, broaden our overall expertise in the pharmaceutical sector and more broadly in capital markets, and complement extremely well the existing skills on our Board. We look forward to working with them to advance our business strategy.
 
“In addition, the decision to implement an accelerated share repurchase program demonstrates our  focus on enhancing shareholder returns as we continue to capitalize on our long-term opportunities,” Caforio continued.
 
“I am pleased to welcome Bob, Matt and Ted to the Board, and know that their unique skill sets and experience will be invaluable to the company going forward,” said Lamberto Andreotti, chairman of the Board. “As I announced in December, I will be retiring as chairman, effective May 2, 2017. I am happy to be leaving with such a strong Board in place and am confident Bristol-Myers Squibb has a bright future.”
 
Bristol-Myers Squibb noted that, since JANA Partners LLC (“JANA”) became a Bristol-Myers Squibb shareholder in the fourth quarter of 2016, members of the Board and management have engaged in discussions with representatives of JANA to better understand their views. Today’s Board appointments follow discussions between the two parties regarding the Board.
 
“These three new independent directors will add valuable industry knowledge and fresh perspectives to the Board, and shareholders stand to reap a substantial benefit from the company's sizable investment in its undervalued shares,” said Barry Rosenstein, founder and managing partner of JANA. “These are two very positive developments for all Bristol-Myers Squibb shareholders.”
 
Togo D. West, Jr., the board’s lead independent director, said, “Bristol Myers-Squibb benefits from a strong Board that comprises leaders who have diverse expertise relevant to the company’s strategy and mission. We welcome Bob, Matt and Ted to the Board and look forward to their contributions.”
 
“Bristol-Myers Squibb is widely regarded as an innovator and a leader with a strong portfolio of assets that will help drive value for shareholders,” said Samuels. “I look forward to working with my colleagues on the Board to continue advancing the company’s important mission.”
 
“I am honored to join the Bristol-Myers Squibb Board and to work alongside some of the great minds in science and medicine,” said Emmens. “With a diverse portfolio and a strong pipeline, I am confident that Bristol-Myers Squibb will continue to find solutions for patients with high unmet medical needs.”
 
“I am pleased to be joining the Board during a period of innovation and scientific discovery,” said Bertolini. “I look forward to joining my fellow directors and the management team in helping Bristol-Myers Squibb with the compelling opportunities ahead.”

 
Accelerated Share Repurchase
 
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC  and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock. The company expects to fund the repurchase with a combination of debt and cash. Approximately 80 percent of the shares to be repurchased under the transaction will be received by Bristol-Myers Squibb on February 28, 2017. The total number of shares ultimately repurchased under the program will be determined upon final settlement and will be based on a discount to the volume-weighted average price of Bristol-Myers Squibb’s common stock during the ASR period. The program is part of Bristol-Myers Squibb’s existing share repurchase authorization. Bristol-Myers Squibb anticipates that all repurchases under the ASR will be completed by the end of the second quarter of 2017. Bristol-Myers Squibb notes that it is commencing a 10b5-1 plan to facilitate continuous stock repurchase activity by the company.

Robert J. Bertolini
 
Bob Bertolini, who currently serves on the boards of Charles River Laboratories and Actelion Pharmaceuticals Ltd., is the former president and CFO of Bausch & Lomb. Previously, Bertolini served as executive vice president and CFO at Schering-Plough Corporation and as a Partner and Pharmaceutical Industry Practice Leader at PricewaterhouseCoopers LLC. He brings extensive  financial and accounting expertise and significant strategic and operational leadership experience in the biopharmaceutical industry to the Board of Bristol-Myers Squibb.

Matthew W. Emmens
 
Matt Emmens is the former chairman, president and CEO of Vertex Pharmaceuticals. Prior to Vertex, Emmens served as chairman and CEO of Shire Pharmaceuticals and as president and CEO of Astra Merck, the joint venture between Merck and Astra AB. He brings to the Board of Bristol-Myers Squibb more than 40 years of experience in the biopharmaceutical industry, with significant management, business development and operations expertise.

 
Theodore R. Samuels
 
Ted Samuels, who currently serves on the boards of Perrigo Company plc and Stamps.com, has more than 35 years of financial industry experience. As the former president of Capital Guardian Trust Company and a former global equity portfolio manager at Capital Group, Samuels has extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making.

Morgan Stanley is serving as financial advisor to Bristol-Myers Squibb and Kirkland & Ellis LLP  is serving as legal counsel. Covington & Burling LLP is serving as legal counsel to Bristol-Myers Squibb in connection with the ASR.

About Bristol-Myers Squibb
 
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

Statement on Cautionary Factors

These materials contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate," "estimates," "should," "expect," "guidance," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.
 
These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions, the ultimate outcome of any litigation matter, and our level of indebtedness. These factors also include the company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
 
Contacts
Bristol-Myers Squibb
Media:
Laura Hortas
609-252-4587
laura.hortas@bms.com
or
Joele Frank, Wilkinson Brimmer Katcher
Joele Frank / Andy Brimmer / Jamie Moser
212-355-4449

Investors:
John Elicker
609-252-4611
john.elicker@bms.com
 
 GRAPHIC 3 image00003.jpg begin 644 image00003.jpg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end